Propafenone Versus Amiodarone in Septic Shock

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Arrhythmias accompany septic shock in increased rates than in other ICU cohorts and their presence and management are related to patient´s prognosis. 1c class antiarrhythmics are seldom administered in intensive care due to a dose dependent toxicity published in case reports and unfavourable outcome reported in a few prospective trials done on cardiology patients. The papers on 1c class antiarrhythmics do not take into consideration a complex haemodynamic assessment using echocardiography. The authors have recently presented a retrospective study on SV arrhythmias in septic shock patients demonstrating favourable effect and safety of propafenone which showed higher antiarrhythmic efficacy than amiodarone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charles University, Czech Republic
• Treatments: Amiodarone; Anti-Arrhythmia Agents; Propafenone

Criteria

Inclusion Criteria:

• Septic shock with a new onset SV arrhythmia

• LV systolic function normal to moderately reduced according to echocardiography.

Exclusion Criteria:

• Severe LV systolic dysfunction

• More than 1st degree AV block

• High dose vasopressor therapy with continuous noradrenaline > 1.0 ug/kg.min

• Known intolerance to amiodarone or propafenone

• Absence of septic shock

• Chronic AF

• Dependence on pacemaker

• Status after MAZE procedure